Tarceva’s Lack Of EGFR Status Data Reflects “Emerging Problem” With Targeted Oncologics, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA review documents for Genentech/OSI’s lung cancer therapy suggest the agency should “proactively” pursue inclusion of receptor status data for targeted anticancer drugs. Tarceva’s potential lack of survival benefit in receptor-negative patients observed in Phase III subgroup led FDA to require postmarketing studies, despite OSI’s insistence that EGFR status is “not important.”
You may also be interested in...
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.